NCT05851677 Disitamab Vedotin (RC48-ADC) in Breast Cancer
| NCT ID | NCT05851677 |
| Status | Recruiting |
| Phase | — |
| Sponsor | RenJi Hospital |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 45 participants |
| Start Date | 2023-06-01 |
| Primary Completion | 2027-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 45 participants in total. It began in 2023-06-01 with a primary completion date of 2027-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
Eligibility Criteria
Inclusion Criteria: * Histologically confirmed breast cancer; * Prior or current use of Disitamab vedotin (RC48-ADC); Exclusion Criteria: * Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.
Contact & Investigator
Wenjin Yin, M.D.
PRINCIPAL INVESTIGATOR
Renji Hospital,School of Medicine, Shanghai Jiaotong University
Frequently Asked Questions
Who can join the NCT05851677 clinical trial?
This trial is open to participants of all sexes, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05851677 currently recruiting?
Yes, NCT05851677 is actively recruiting participants. Contact the research team at yinwenjin@renji.com for enrollment information.
Where is the NCT05851677 trial being conducted?
This trial is being conducted at Shanghai, China.
Who is sponsoring the NCT05851677 clinical trial?
NCT05851677 is sponsored by RenJi Hospital. The principal investigator is Wenjin Yin, M.D. at Renji Hospital,School of Medicine, Shanghai Jiaotong University. The trial plans to enroll 45 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.